Quarterly report pursuant to Section 13 or 15(d)

Segment Information (Tables)

Segment Information (Tables)

6 Months Ended

Jun. 30, 2023

The following table summarizes the segment information (in thousands):


	Three Months Ended June 30,				Six Months Ended June 30,
	2023		2022		2023		2022
Net revenues:
Clinical Services	$	123,156	$	105,635	$	238,025	$	204,426
Advanced Diagnostics	23,761		19,437		46,112		37,815
Total revenue	146,917		125,072		284,137		242,241

Cost of revenue:
Clinical Services(1)	71,746		67,035		139,038		132,302
Advanced Diagnostics(2)	15,280		14,091		30,394		27,761
Total cost of revenue	87,026		81,126		169,432		160,063

Gross Profit:
Clinical Services	51,410		38,600		98,987		72,124
Advanced Diagnostics	8,481		5,346		15,718		10,054
Total gross profit	$	59,891	$	43,946	$	114,705	$	82,178

(1) Clinical Services cost of revenue for both the three months ended June 30, 2023 and June 30, 2022 includes $4.3 million of amortization of acquired Inivata developed technology intangible assets. Clinical Services cost of revenue for both the six months ended June 30, 2023 and June 30, 2022 includes $8.5 million of amortization of acquired Inivata developed technology intangible assets.

(2) Advanced Diagnostics cost of revenue for both the three months ended June 30, 2023 and June 30, 2022 includes $0.6 million of amortization of acquired Inivata developed technology intangible assets. Advanced Diagnostics cost of revenue for both the six months ended June 30, 2023 and June 30, 2022 includes $1.2 million of amortization of acquired Inivata developed technology intangible assets.